Pulocimab - CISMeF

Preferred Label : Pulocimab;

NCIt synonyms : Anti-VEGFR2 Monoclonal Antibody AK109; Anti-VEGFR-2 Monoclonal Antibody AK109;

NCIt definition : A human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2; VEGFR2), with potential anti-angiogenesis and antineoplastic activities. Upon administration, pulocimab specifically binds to and inhibits VEGFR-2 on vascular endothelial cells, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR-2, a tyrosine-protein kinase that plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells, is overexpressed in certain tumor types.;

UNII : FDL8DA4XV4;

CAS number : 2428381-49-9;

Molecule name : AK 109; AK-109;

NCI Metathesaurus CUI : CL1664826;

Détails

Origin ID

C182005;

UMLS CUI

C5667235;

Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Vascular Endothelial Growth Factor Receptor 2 [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients